Insulin Glargine News and Research

RSS
Type 2 diabetes can be reversed with intensive medical treatment, study shows

Type 2 diabetes can be reversed with intensive medical treatment, study shows

New report reveals prescription medication costs may increase up to 13% in 2016

New report reveals prescription medication costs may increase up to 13% in 2016

Drug combination improves glucose control in Type 2 diabetes patients

Drug combination improves glucose control in Type 2 diabetes patients

IDegLira injections more effective than traditional insulin injections in treating type-2 diabetes patients

IDegLira injections more effective than traditional insulin injections in treating type-2 diabetes patients

Sanofi seeks FDA NDA approval for once-daily fixed-ratio combination of insulin glargine and lixisenatide

Sanofi seeks FDA NDA approval for once-daily fixed-ratio combination of insulin glargine and lixisenatide

Basaglar (insulin glargine injection) approved to improve glycemic control in diabetes patients

Basaglar (insulin glargine injection) approved to improve glycemic control in diabetes patients

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

Sanofi announces FDA approval of Toujeo insulin to improve glycemic control in people with diabetes

Sanofi announces FDA approval of Toujeo insulin to improve glycemic control in people with diabetes

Study clarifies association between metformin use and lung cancer risk

Study clarifies association between metformin use and lung cancer risk

Lilly and Boehringer Ingelheim's insulin glargine product gets marketing approval from EC

Lilly and Boehringer Ingelheim's insulin glargine product gets marketing approval from EC

Lilly and Boehringer Ingelheim's Basaglar (insulin glargine injection) gets FDA's tentative approval

Lilly and Boehringer Ingelheim's Basaglar (insulin glargine injection) gets FDA's tentative approval

Adocia announces positive final results for first clinical trial of BioChaperone Combo

Adocia announces positive final results for first clinical trial of BioChaperone Combo

Adocia reports positive preliminary results for first clinical trial of BioChaperone Combo

Adocia reports positive preliminary results for first clinical trial of BioChaperone Combo

Merck, Samsung Bioepis agree to develop, commercialize MK-1293 for treatment of diabetes

Merck, Samsung Bioepis agree to develop, commercialize MK-1293 for treatment of diabetes

Lilly, Boehringer Ingelheim announce FDA acceptance of NDA filing for new insulin glargine product

Lilly, Boehringer Ingelheim announce FDA acceptance of NDA filing for new insulin glargine product

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Insulin degludec has reduced risk of recurrent hypoglycemia than insulin glargine

Insulin degludec has reduced risk of recurrent hypoglycemia than insulin glargine